<DOC>
	<DOCNO>NCT00172081</DOCNO>
	<brief_summary>This 18-month , double-blind , placebo-controlled , Phase III trial 12-month interim analysis effect ALX1-11 , recombinant human parathyroid hormone ( 1-84 ) ( rhPTH [ 1-84 ] ) , fracture incidence woman postmenopausal osteoporosis , TOP study .</brief_summary>
	<brief_title>TOP : Recombinant Human Parathyroid Hormone ( ALX1-11 ) Fracture Incidence Women With Postmenopausal Osteoporosis</brief_title>
	<detailed_description>Parathyroid hormone ( PTH ) , polypeptide consist 84 amino acid synthesize secrete parathyroid gland , principal regulator calcium homeostasis concert action kidney , intestine bone . Parathyroid hormone exert action bone release calcium extracellular fluid process bone remodel also maintain serum calcium concentration , exact mechanism fully understood . In circumstance , PTH may exert anabolic action bone stimulate osteoblast proliferation mature osteoblast function . The net effect exogenous PTH administration bone turnover depend pattern delivery . A continuous long-term infusion give net decrease trabecular bone volume , whereas daily single injection result net increase . NPS Allelix Corp. develop ALX1-11 , recombinant human parathyroid hormone ( 1-84 ) , treatment osteoporosis . ALX1-11 identical endogenous intact 84 amino acid human hormone self-administered daily basis subcutaneous ( sc ) injection . Currently , approve therapy osteoporosis capable stimulate formation new bone normal composition structure . Most therapy development anti-catabolic prevent bone loss ( e.g. , estrogen replacement , bisphosphonates , calcitonin ) . ALX1-11 potential stimulate new bone formation osteoporotic patient , thereby increase bone mass prevent fracture . Patients moderately severely reduced bone density fracture would expect benefit treatment , thereby improve functional status alleviate symptom .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Women postmenopausal least one year since last menstruation . Women 4554 year age follow bone mineral density ( BMD ) and/or vertebral fracture : BMD 3.0 standard deviation ( SDs ) peak bone mass young female lumbar spine , femoral neck , total hip ; BMD 2.5 SDs peak bone mass young female lumbar spine , femoral neck total hip presence vertebral fracture verify central image organization patient enrol study . Women 55 year age follow BMD and/or vertebral fracture : BMD 2.5 SDs peak bone mass young female lumbar spine , femoral neck total hip ; BMD 2.0 SDs peak bone mass young female lumbar spine , femoral neck total hip presence vertebral fracture verify central image organization patient enrol study . The following type vertebral fracture consider patient enrollment trial : Pathological fracture due malignant disease infection Fractures due excessive trauma sufficient cause fracture young individual normal bone mass Women ability selfadminister daily injection designee give injection Women capable understand give write , voluntary inform consent clinical trial screen visit A. Vertebral Deformity : Patient 5 vertebral ( thoracic lumbar ) deformities Patient 2 lumbar vertebral deformity ( L1 L4 ) Severe lumbar scoliosis ( &gt; 15 degree ) precludes reliable evaluation dual xray absorptiometry ( DXA ) B. DXA Imaging : Inability DXA scan perform . C. History Concurrent Illness : Disorders immunity Endocrine system Gastrointestinal system Kidney collect system Liver , biliary tract pancreatic system Musculoskeletal system Neoplasia Nervous system Vascular , respiratory cardiac system Significant diseases disorder determine history , physical exam laboratory screen judge Principal Investigator significant . D. Concurrent Medication : Any patient require medication washout ( discontinuation ) specify may start study drug dose 2 week stabilization treatment calcium vitamin D3 supplement . All exception document case report form ( CRF ) . Patients enrol clinical trial receive follow therapy time : Any PTH PTH analog [ e.g. , rhPTH ( 184 ) , PTH ( 134 ) , PTHrP analogs ] Fluoride Strontium Patients must follow agent specify time enter screen phase clinical trial : Any investigational drug ( 30 day ) Anabolic steroid androgen ( 6 consecutive month ) Active vitamin D3 metabolite analog ( 90 day ) Systemic corticosteroid , 5 mg/day prednisone systemic corticosteroid formulation equivalent 5 mg/day prednisone ( 12 consecutive month ) . A patient enrol study need receive acute bolus steroid ( oral injectable ) selflimited illness may continue treatment study follow requirement meet : 1 . Exposure steroid limit 30 consecutive day 2 . The maximal dose steroid ( prednisone equivalent ) limit 225 mg ( 7.5 mg day 30 day ) 3 . The illness acute nature expect recur remain treatment period study Daily inhale corticosteroid unless dose 1200 mg/day beclomethasone . Bisphosphonates , include investigational bisphosphonates . Intravenous ( IV ) pamidronate . Patient must receive pamidronate specifically treat osteoporosis . Patient receive ONE IV dose pamidronate 12 month immediately precede screen visit . Cyclical etidronate . Exposure cyclical etidronate must less equal 6 month standard dose ( e.g . 400 mg/day ) . Patient exposure cyclical etidronate 9 month prior screen visit . Phenytoin seizure control . If patient receive phenytoin within five year screen visit , patient exclude study . The patient may continue screen process 15 year pass since last dose phenytoin time screen visit . If phenytoin use 515 year screen visit patient receive phenytoin less 2 month . Patients may enrol stabilize follow therapy specify amount time : * Thyroid hormone ( &lt; 0.1 mg/day thyroxine ) therapy least 6 month . * Stable dosage thiazide least 3 consecutive month . All patient must stop follow therapy least 4 week prior screen visit remain therapy remainder clinical trial . Screening laboratory must perform washout complete . However , image study ( BMD , Xrays ) may perform prior start calcitonin , estrogen , selective estrogen receptor modulation ( SERM ) washout . Calcitonin Estrogen replacement therapy oral , transdermal intramuscular administration SERM drug , e.g. , tamoxifen , raloxifene , Evista Vaginal application estrogencontaining cream unless dose conjugate estrogen estradiol* Cytostatics , e.g. , azathioprine , recombinant human tumor necrosis fusion ( Fc ) protein , monoclonal antibody tumor necrosis factor ( e.g. , remicade [ infliximab ] ) The drug class tetracycline Medication know affect metabolism bone ( Principal Investigator discus Project Medical Officer patient exclude enrollment ) E. Miscellaneous Concurrent Medications : Methotrexate Intraarticular injection Patients chronic , active joint disease exclude Phase III study . Patients may receive maximum one intraarticular injection ( ONE JOINT ONLY ) every 6 month participate Phase III study . The dose corticosteroid inject exceed antiinflammatory equivalent dose prednisone 40 mg suspension . The dose volume adjust downward appropriate size joint . Provera acceptable concomitant medication use accord label instruction . F. Laboratory Values Physical Examination Findings : Serum calcium great 10.7 mg/dL ( 2.66 mmol/L ) . At screening , serum calcium abnormal , patient may additional evaluation describe ONCE : 1 . Discontinue oral calcium vitamin D3 supplement . 2 . Repeat fast serum calcium level two week later . 3 . If fasting serum calcium level still abnormal , patient discontinue study . 4 . If repeat fast serum calcium normal , patient supplemental calcium vitamin D3 restart time study drug dosing , without go twoweek stabilization period . Serum creatinine &gt; 1.5 mg/dL ( 132.6 mmol/L ) Urinary calcium creatinine ratio great equal 1 . At screen , patient 's urinary calcium creatinine ratio abnormal , patient may additional evaluation describe ONCE : 1 . Discontinue oral calcium vitamin D3 supplement . 2 . Repeat fast urine calcium creatinine ratio two week later . 3 . If fasting urinary calcium creatinine ratio still abnormal , patient discontinue study . 4 . If repeat fast urinary calcium creatinine ratio normal , patient supplemental calcium vitamin D3 restart time study drug dosing , without go twoweek stabilization period . Total serum alkaline phosphatase &gt; 130 U/L except note Argentina ( 311 U/L ) ; Brazil ( 278 U/L ) ; Mexico ( 159 U/L ) . Any clinically significant abnormal value judge investigator Body weight 40 kg G. Substance Abuse : Alcohol and/or drug abuse H. Psychiatric Disease : Current history psychiatric disease would interfere ability comply clinical trial protocol I . Compliance : Suspected confirm poor compliance complete clinical trial evaluation and/or clinical trial require questionnaire</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>Post-menopausal</keyword>
	<keyword>Osteoporosis</keyword>
	<keyword>Parathyroid Hormone</keyword>
	<keyword>PTH</keyword>
	<keyword>ALX1-11</keyword>
</DOC>